Moderna, Inc. (MRNA) shares surged 5.86% in pre-market trading following the release of its impressive third-quarter financial results. The biotechnology company significantly outperformed analysts' expectations, demonstrating resilience in its COVID-19 vaccine business and overall financial health.

The company reported a quarterly loss of $0.51 per share, substantially better than the expected loss of $2.11 per share according to LSEG IBES data. Moderna's revenue for the quarter reached $1.02 billion, comfortably surpassing the estimated $886.5 million. The strong performance was largely driven by COVID-19 vaccine sales, which accounted for $971 million of the total revenue.

Looking ahead, Moderna provided a full-year revenue outlook ranging from $1.6 billion to $2.0 billion, in line with the current market estimate of $1.90 billion. The company also announced plans to refile its MRNA-1083 product with Health Canada in 2025, while awaiting further guidance from the U.S. FDA on refiling. This forward-looking statement, coupled with the robust quarterly results, appears to have boosted investor confidence, contributing to the significant pre-market stock price increase.